The invention relates to an at least three-layer transdermal therapy system (TTS), which contains, in particular, rotigotine as an active ingredient. The TTS comprises an active ingredient-containing central layer, which comprises at least one hygroscopic polymer or copolymer, an inner, active ingredient-permeable layer and an outer layer.